ReviewCurrent osteoporosis reports2014
Clinical considerations of regenerative medicine in osteoporosis.
Review in Current osteoporosis reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Advancing application of mesenchymal stem cell-based bone tissue regeneration.Bioactive materials · 2021Review
- MEF2C regulates osteoclastogenesis and pathologic bone resorption via c-FOS.Bone research · 2021Article
- A study of dynamic contrast-enhanced MR imaging features and influence factors of pelvic bone marrow in adult females.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019Article
- Human iPSC-derived MSCs (iMSCs) from aged individuals acquire a rejuvenation signature.Stem cell research & therapy · 2019Article
- Adipose mesenchymal stem cells from osteoporotic donors preserve functionality and modulate systemic inflammatory microenvironment in osteoporotic cytotherapy.Scientific reports · 2018Article
- TGFβ-induced switch from adipogenic to osteogenic differentiation of human mesenchymal stem cells: identification of drug targets for prevention of fat cell differentiation.Stem cell research & therapy · 2016Article
- miR-195 in human primary mesenchymal stromal/stem cells regulates proliferation, osteogenesis and paracrine effect on angiogenesis.Oncotarget · 2016Article
- Rapid increase in marrow fat content and decrease in marrow perfusion in lumbar vertebra following bilateral oophorectomy: an MR imaging-based prospective longitudinal study.Korean journal of radiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis-related fractures may severely limit activities of daily living and may require bed rest, which may become life threatening in elderly people. Osteoporosis has attracted much attention recently because of its severe effects on the daily activities of older people and because it is now treatable, thanks to recent advances in drug discovery. However, these medications have yet to reduce fully the number of fracture cases. On the other hand, declines in the number and function of osteoblasts and mesenchymal stem cells (MSCs) in the bone marrow and within the periosteum lead to reduced osteogenesis and bone formation. Thus, bone regeneration, through induction of MSCs, provides a rational therapeutic strategy for preventing or treating age-related osteoporosis. In this review, I summarize cell-related issues in osteoporosis, stem cell candidates for cell-based therapy, and possible therapeutic strategies for osteoporosis.
Indexed as
Identifiers
24619559What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.